State Street
NRIX icon

State Street’s Nurix Therapeutics NRIX Stock Holding History

State Street’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.7M Buy
5,141,195
+1,581,694
+44% +$26.2M ﹤0.01% 1501
2025
Q4 		$67.5M Buy
3,559,501
+697,114
+24% +$10M ﹤0.01% 1580
2025
Q3 		$26.4M Buy
2,862,387
+330,233
+13% +$3.43M ﹤0.01% 2090
2025
Q2 		$28.8M Sell
2,532,154
-329,066
-12% -$3.56M ﹤0.01% 1982
2025
Q1 		$34M Buy
2,861,220
+57,960
+2% +$969K ﹤0.01% 1834
2024
Q4 		$52.8M Buy
2,803,260
+431,989
+18% +$9.9M ﹤0.01% 1690
2024
Q3 		$53.3M Sell
2,371,271
-337,262
-12% -$7.64M ﹤0.01% 1675
2024
Q2 		$56.5M Sell
2,708,533
-20,803
-0.8% -$324K ﹤0.01% 1612
2024
Q1 		$40.1M Buy
2,729,336
+1,808,014
+196% +$19.4M ﹤0.01% 1836
2023
Q4 		$9.51M Sell
921,322
-852,746
-48% -$5.84M ﹤0.01% 2620
2023
Q3 		$13.9M Sell
1,774,068
-151,658
-8% -$1.38M ﹤0.01% 2400
2023
Q2 		$19.2M Sell
1,925,726
-309,552
-14% -$3.16M ﹤0.01% 2263
2023
Q1 		$19.8M Sell
2,235,278
-272,709
-11% -$2.84M ﹤0.01% 2237
2022
Q4 		$27.5M Buy
2,507,987
+195,763
+8% +$2.36M ﹤0.01% 2017
2022
Q3 		$30.1M Buy
2,312,224
+195,453
+9% +$3.09M ﹤0.01% 1941
2022
Q2 		$26.8M Sell
2,116,771
-185,773
-8% -$2.11M ﹤0.01% 2040
2022
Q1 		$32.3M Buy
2,302,544
+744,832
+48% +$13.2M ﹤0.01% 2054
2021
Q4 		$45.1M Sell
1,557,712
-75,419
-5% -$2.29M ﹤0.01% 1878
2021
Q3 		$48.9M Sell
1,633,131
-226,337
-12% -$6.98M ﹤0.01% 1823
2021
Q2 		$49.3M Buy
1,859,468
+481,606
+35% +$14.1M ﹤0.01% 1860
2021
Q1 		$42.8M Buy
1,377,862
+926,630
+205% +$35.1M ﹤0.01% 1859
2020
Q4 		$14.8M Buy
451,232
+319,559
+243% +$10.6M ﹤0.01% 2412
2020
Q3 		$4.6M Buy
+131,673
New +$3.32M ﹤0.01% 2825

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street's NRIX Position: Q1 2026 in Review

State Street increased its Nurix Therapeutics (NRIX) stake by 44% in Q1 2026, buying an estimated $26.2M and bringing the position to 5,141,195 shares worth $79.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1501.

State Street first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • State Street held 5,141,195 shares of Nurix Therapeutics worth $79.7M as of Q1 2026.
  • State Street bought 1,581,694 Nurix Therapeutics shares in Q1 2026, an estimated $26.2M.
  • Nurix Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1501 holding.
  • State Street first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.